RELMADA THERAPEUTICS, INC. (RLMD) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -4.54M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-4.54M | (m) |
| 2026-03-31 | (m) | $-1.49M | (m) |
| 2025-12-31 | (m) | $-57.39M | (m) |
| 2025-09-30 | (m) | $-56.17M | (m) |
| 2025-06-30 | (m) | $-67.81M | (m) |
| 2025-03-31 | (m) | $-75.71M | (m) |
| 2024-12-31 | (m) | $-79.98M | (m) |
| 2024-09-30 | (m) | $-86.49M | (m) |
| 2024-06-30 | (m) | $-86.76M | (m) |
| 2024-03-31 | (m) | $-94.30M | (m) |
| 2023-12-31 | (m) | $-98.79M | (m) |
| 2023-09-30 | (m) | $5.73M | (m) |
| 2023-06-30 | (m) | $-11.69M | (m) |
| 2023-03-31 | (m) | $-26.32M | (m) |
| 2022-12-31 | (m) | $-157.04M | (m) |
| 2022-09-30 | (m) | $-153.48M | (m) |
| 2022-06-30 | (m) | $-156.67M | (m) |
| 2022-03-31 | (m) | $-143.28M | (m) |
| 2021-12-31 | (m) | $-125.75M | (m) |
| 2021-09-30 | (m) | $-112.14M | (m) |
| 2021-06-30 | (m) | $-86.43M | (m) |
| 2021-03-31 | (m) | $-71.00M | (m) |
| 2020-12-31 | (m) | $-59.46M | (m) |
| 2020-09-30 | (m) | $-43.22M | (m) |
| 2020-06-30 | (m) | $-29.99M | (m) |
| 2020-03-31 | (m) | (m) | (m) |
| 2019-12-31 | (m) | $-15.01M | (m) |
| 2019-09-30 | (m) | $-17.61M | (m) |
| 2019-06-30 | (m) | $-17.32M | (m) |
| 2019-03-31 | (m) | $-16.55M | (m) |
| 2018-12-31 | (m) | $-17.06M | (m) |
| 2018-09-30 | (m) | $-11.36M | (m) |
| 2018-06-30 | (m) | $-8.96M | (m) |
| 2018-03-31 | (m) | $-7.24M | (m) |
| 2017-12-31 | (m) | $-6.02M | (m) |
| 2017-09-30 | (m) | $-5.63M | (m) |
| 2017-06-30 | (m) | $-6.29M | (m) |
| 2017-03-31 | (m) | $-7.97M | (m) |
| 2016-12-31 | (m) | $-7.85M | (m) |
| 2016-09-30 | (m) | $-9.28M | (m) |
| 2016-06-30 | (m) | $-2.97M | (m) |
| 2016-03-31 | (m) | $6.39M | (m) |
| 2015-12-31 | (m) | $5.78M | (m) |
| 2015-09-30 | (m) | $13.70M | (m) |
| 2015-06-30 | (m) | $-20.80M | (m) |
| 2015-03-31 | (m) | $-54.68M | (m) |
| 2014-12-31 | (m) | $-45.72M | (m) |
| 2014-09-30 | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) |
| 2014-03-31 | (m) | $-12.75M | (m) |
| 2014-02-28 | (m) | $-49.35K | (m) |
| 2013-12-31 | (m) | $-19.87M | (m) |
| 2013-11-30 | (m) | $-50.37K | (m) |
| 2013-09-30 | (m) | (m) | (m) |
| 2013-08-31 | (m) | $-45.02K | (m) |
| 2013-05-31 | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) |
| 2013-02-28 | (m) | (m) | (m) |
| 2012-12-31 | (m) | $-6.86M | (m) |
| 2012-11-30 | (m) | (m) | (m) |
| 2012-08-31 | (m) | $-12.05K | (m) |
| 2012-05-31 | (m) | (m) | (m) |
| 2012-02-29 | (m) | (m) | (m) |
| 2011-12-31 | (m) | $-873.97K | (m) |
| 2011-08-31 | (m) | (m) | (m) |
| 2010-12-31 | (m) | $-830.92K | (m) |
| 2009-12-31 | (m) | $-1.14M | (m) |
| 2008-12-31 | (m) | $-1.77M | (m) |
| 2007-12-31 | (m) | $217.20K | (m) |
| 2006-12-31 | (m) | $-1.03M | (m) |
| 2005-12-31 | (m) | $-1.02M | (m) |
| 2004-12-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |